Arcus Biosciences, Inc.
Every calculator, already run for RCUS
Open the full toolkit →You have the numbers on RCUS. Get the argument.
A written report on which of these readings actually decide the outcome for Arcus Biosciences, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
13 analysts covering RCUSAnalyst Price Target Disagreement for Arcus Biosciences, Inc.
Wall Street's bull case implies +58% from the current price; the bear case implies -22%. A 81% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for RCUS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1…
RCUS — frequently asked
Is RCUS a buy right now?
Wall Street's consensus rating on Arcus Biosciences, Inc. is none across 13 analysts, with a mean price target of $38.33 (+29% vs. the current $29.66). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is RCUS's next earnings date?
Arcus Biosciences, Inc. is next scheduled to report earnings around Oct 27, 2026. A full RCUS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Arcus Biosciences, Inc.?
Analysts covering Arcus Biosciences, Inc. (RCUS) range from a bear-case target of $23.00 to a bull-case high of $47.00, with a mean consensus target of $38.33 across 12 analysts. The spread of $24.00 (81% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Arcus Biosciences, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Arcus Biosciences, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full RCUS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Arcus Biosciences, Inc., in minutes. 3 free reports included with every account — no credit card required.